Results 141 to 150 of about 18,508 (192)
Post-market surveillance of antiretroviral drug quality in Tanzania in the context of rising HIV drug resistance. [PDF]
Sci RepMlugu EM, Mhagama JB, Sangeda RZ, Kunambi PP, Samwel T, Shiletiwa N, Gotora G, Chambiri SM, Matiko D, Hipolite D, Mwalwisi YH, Fimbo AM. +11 moreeuropepmc +1 more sourceHIV-1 integrase variability and relationship with drug resistance in antiretroviral-naive and -experienced patients with different HIV-1 subtypes [PDF]
, 2017 Alloui, C., Alloui, C., Amiel, C., Amiel, C., Amiel, C., Assoumou, L., Assoumou, L., Auvray, C., Auvray, C., Bertsch, S., Bertsch, S., Bettinger, D., Bettinger, D., Bocket, L., Bocket, L., Bourlet, T., Bourlet, T., Bouvier-Alias, M., Bouvier-Alias, M., Brun-Vezinet, F., Brun-Vezinet, F., Calvez, V., Calvez, V., Chaix, M. L., Chaix, M. L., Chaplain, C., Chaplain, C., de Rougemont, A., de Rougemont, A., Delaugerre, C., Delaugerre, C., Descamps, D., Descamps, D., Descamps, D., Ferré, V., Ferré, V., Flandre, P., Flandre, P., Flandre, Philippe, Fleury, H., Guinard, J., Guinard, J., Haim-Boukobza, S., Haim-Boukobza, S., Houssaïni, A., Krivine, A., Krivine, A., Leguillou-Guillemette, H., Leguillou-Guillemette, H., Maillard, A., Maillard, A., Marcelin, A. G., Marcelin, A. G., Marcelin, A. G., Marque-Juillet, S., Marque-Juillet, S., Masquelier, B., Masquelier, B., Masquelier, B., Mirand, A., Mirand, A., Montes, B., Montes, B., Morand-Joubert, L., Morand-Joubert, L., Pallier, C., Pallier, C., Peytavin, G., Peytavin, G., Pinson, P., Pinson, P., Plantier, J. C., Plantier, J. C., Plantier, J. C., Poveda, J. D., Poveda, J. D., Raymond, S., Raymond, S., Reigadas, S., Reigadas, S., Reigadas, S., Rogez, S., Rogez, S., Roussel, C., Roussel, C., Ruffault, A., Schneider, V., Schneider, V., Schvoerer, E., Schvoerer, E., Signori-Schmuck, A., Signori-Schmuck, A., Soulié, C., Soulié, C., Tamalet, C., Tamalet, C., Trabaud, M. A., Vallet, S., Vallet, S., Yerly, S., Yerly, S., Yerly, S. +101 morecore HIV persistence in tissues on dolutegravir-based therapy is not associated with resistance mutations to dolutegravir. [PDF]
Commun Med (Lond)Mchantaf G, Melard A, Da Silva K, Gardiennet E, Chaillon A, Lefebvre B, Ghosn J, Robineau O, Viard JP, Adoux L, Lemoine F, Barrail-Tran A, Orr S, Coulibaly F, Meyer L, Cheret A, Avettand-Fenoel V. +16 moreeuropepmc +1 more sourceLingering sex and age disparities in dolutegravir uptake among adults with HIV: a multicountry observational cohort study. [PDF]
BMJ Glob HealthBrazier E, Romo ML, Ciaranello AL, Odhiambo F, Pujari S, Murenzi G, Kasozi C, Kiertiburanakul S, Nsonde DM, Muyindike W, Khol V, Lelo P, Lyamuya R, Lee MP, Nash D. +14 moreeuropepmc +1 more sourceFactors Associated With Incomplete Adherence to Dolutegravir-Based Antiretroviral Therapy in Southwestern Uganda. [PDF]
J Acquir Immune Defic SyndrNutt CT, Muyindike WR, Nanfuka V, Komukama N, Barigye IT, Kansiime L, Tumusiime J, Omoding D, Aung TN, Stuckwisch A, Hedt-Gauthier B, Hoeppner SS, Marconi VC, Moosa MS, Gupta RK, Siedner MJ, McCluskey SM. +16 moreeuropepmc +1 more sourceNovel integrase mutations linked to genotypic DTG resistance in African non-B HIV-1 strains: the DTG RESIST study. [PDF]
J Antimicrob ChemotherHan N, Loosli T, Sauermann M, Çelikağ İ, Anderegg N, Baye BC, Bolton Moore C, Buzaalirwa L, Byakwaga H, Chimbetete C, Ebasone PV, Goodrich S, Huwa J, Kasozi C, Mafoua A, Massamba AC, Messou E, Minga A, Murenzi G, Muula G, Muyindike W, Naidoo SJ, Nsonde DM, Poda AG, Ramdé R, Semeere A, Singh L, Günthard HF, Egger M, Giandhari J, Lessells R, Kouyos RD. +31 moreeuropepmc +1 more source
